All Stories

ALX lays off 30% of staff to pay for more trials of CD47 blocker

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker.

Mar 5, 2025 - 15:47
 0
ALX lays off 30% of staff to pay for more trials of CD47 blocker
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker.
Read More

Tags:

Previous Article

Alexa+ by Amazon: A Game&Changer in Travel Research and Planning?

Next Article

Trump administration policies could create headwinds across healthcare: Fitch

Related Posts

Corbus posts first US data on challenger to Pfizer’s ADC Padcev

Corbus posts first US data on challenger to Pfizer’s AD...

Feb 14, 2025  0

Inspire Medical discloses DOJ civil false claims investigation

Inspire Medical discloses DOJ civil false claims invest...

Feb 11, 2025  0

IconOVir, 4 years on from flashy launch, sells oncolytic virus to UroGen for $4M in stock

IconOVir, 4 years on from flashy launch, sells oncolyti...

Feb 20, 2025  0